Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lu Si

Showing results (201-210 of 230) with videos related to

Pageof 23
Sort By:
Journal for Immunotherapy of Cancer|January 2, 2023
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapyJie Dai, Xue Bai, Xuan Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Annals of Surgical Oncology|April 10, 2022
An Evidence-Based Staging System for Mucosal Melanoma: A ProposalChuanLiang Cui, Bin Lian, XiaoShi Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous MelanomaJiayi Yu, Junya Yan, Qian Guo, et al.
Journal of the American Academy of Dermatology|September 8, 2022
Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysisXiaoting Wei, Yu Chen, Hong Yao, et al.
Nature Communications|May 15, 2026
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanomaLili Mao, Yumei Lai, Hong Zheng, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
JAMA Oncology|June 1, 2023
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical TrialLili Mao, Bin Lian, Caili Li, et al.
Annals of Surgical Oncology|April 8, 2020
The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral MelanomaXiaoting Wei, Di Wu, Hang Li, et al.
CA: a Cancer Journal for Clinicians|February 19, 2025
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trialLing-Long Tang, Lin Chen, Gui-Qiong Xu, et al.
Pageof 23

Showing results (201-210 of 230) with videos related to

Sort By:
Pageof 23
Journal for Immunotherapy of Cancer|January 2, 2023
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapyJie Dai, Xue Bai, Xuan Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Annals of Surgical Oncology|April 10, 2022
An Evidence-Based Staging System for Mucosal Melanoma: A ProposalChuanLiang Cui, Bin Lian, XiaoShi Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous MelanomaJiayi Yu, Junya Yan, Qian Guo, et al.
Journal of the American Academy of Dermatology|September 8, 2022
Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysisXiaoting Wei, Yu Chen, Hong Yao, et al.
Nature Communications|May 15, 2026
A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanomaLili Mao, Yumei Lai, Hong Zheng, et al.
JAAD International|March 19, 2024
Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort studyXue Bai, Aleigha R Lawless, Juliane A Czapla, et al.
JAMA Oncology|June 1, 2023
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical TrialLili Mao, Bin Lian, Caili Li, et al.
Annals of Surgical Oncology|April 8, 2020
The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral MelanomaXiaoting Wei, Di Wu, Hang Li, et al.
CA: a Cancer Journal for Clinicians|February 19, 2025
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trialLing-Long Tang, Lin Chen, Gui-Qiong Xu, et al.
Pageof 23